Tirzepatide - Weight management in adults

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status for tirzepatide initiation in secondary care for overweight and obesity management. This will enable the Surrey Weight Management Service (SWMS) to initiate appropriate patients with tirzepatide for the same cohort of patients eligible for treatment in primary care (as stated in the NHS E commissioning guidance.)

A BLUE (with specialist initiation from the SWMS) was agreed with prescribing by the SWMS for 12 months prior to transfer of care to primary care prescribers.

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed tirzepatide in primary care for obesity and weight management in line with NICE TA1026.

Tirzepatide in Surrey Heartlands will be available via primary care for patients who fall within the Funding Variation criteria detailed within the NHS England Commissioning .

NB: Tirzepatide weekly injection for use in Type 2 Diabetes should ONLY be used when the primary indication is diabetic control to allow for equity of access to tirzepatide for weight management in line with the national funding variation cohorts. The agreement made in March 2024 by the APC is available here for patients with Type 2 Diabetes: https://surrey.res.services/PAD/Profile/Index/6604

GLP-1 receptor agonists can impact female hormones, including HRT and contraceptives, and reproductive health through various mechanisms.  For further information and advice see links below.